Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who struggle to take daily HIV pills may benefit from long-acting injectable ...

The new study, published in The Lancet, is the first to evaluate a once-yearly injection of an HIV pre-exposure prophylaxis ...

Bridgette J. Picou, LVN, ACLPN, presented research on the lived experiences of women living with HIV and going through ...

Researchers from Imperial College London, working with the University of Oxford and Rockefeller University, have shown ...

Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by ...

Gilead (GILD) stock in focus as its HIV anti-viral lenacapavir shows promise in HIV prevention with once-yearly PrEP ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Pre-exposure prophylaxis (PrEP) is the advent of antiretroviral treatment use for people at increased risk of acquiring HIV-1 ...

HIV prevention medication ‘could one day be a yearly jab’ – study suggests - Yearly doses could reduce barriers people face ...

The Kingdom of Eswatini has the highest HIV/AIDS incidence in the world. However, the mission of the Piggs Peak Partnership ...